and M6223 (an anti-TIGIT antibody) might work better. Nonetheless, a positive result could still speak to the potential of ...

Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...

A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available ...

The biotech’s pipeline features bispecifics against a range of targets, including one candidate that hits PD-L1 and TGFβ and ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to ...

Arcus Biosciences unveiled data from a terminated late-stage study of its TIGIT and PD-1 drug combo that it says supports its ...

Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Read More on ITOS: ...

Among its late-stage pipelines, we assign a very low probability of 10% to its phase 3 project on Ociperlimab, an anti-TIGIT antibody, after Roche failed its TIGIT pivotal trial in July 2024. Hence, ...

EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered with China’s BeiGene.

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus ...